FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361295066> ?p ?o ?g. }

• W4361295066 endingPage "e069641" @default.
• W4361295066 startingPage "e069641" @default.
• W4361295066 abstract "Introduction Cardiac transplantation (CTx) is a life-saving operation that can improve the quality and length of a recipient’s life. Immunosuppression medication, required to prevent rejection, can result in adverse metabolic and renal effects. Clinically significant complications include metabolic effects such as diabetes and weight gain, renal impairment, and cardiac disease such as allograft vasculopathy and myocardial fibrosis. Sodium glucose co-transporter 2 (SGLT2) inhibitors are a class of oral medication that increase urinary excretion of glucose. In patients with type 2 diabetes, SGLT2 inhibitors improve cardiovascular, metabolic and renal outcomes. Similar benefits have been shown in patients with heart failure and reduced ejection fraction irrespective of diabetes status. In patients with post-transplant diabetes mellitus, SGLT2 inhibitors improve metabolic parameters; however, their benefit and safety have not been evaluated in randomised prospective studies. This study will potentially provide a novel therapy to improve or prevent complications (diabetes, kidney failure and heart fibrosis) that occur with immunosuppressive medications. Methods The EMPA-HTx study is a randomised, placebo-controlled trial of the SGLT2 inhibitor empagliflozin 10 mg daily versus placebo in recent CTx recipients. One hundred participants will be randomised 1:1 and commence the study medication within 6–8 weeks of transplantation with treatment and follow-up until 12 months after transplantation. Demographic information, anthropomorphic measurements, pathology tests and cardiac magnetic resonance (CMR) scan will be recorded at baseline and follow-up. Patients will be reviewed monthly during the study until 12 months post-CTx and data will be collected for each patient at each study visit. The overall aim of the study is to assess the safety and efficacy of empagliflozin in CTx recipients. The primary outcome is glycaemic improvement measured as change in glycated haemoglobin and/or fructosamine. Key secondary outcomes are cardiac interstitial fibrosis measured by CMR and renal function measured by estimated glomerular filtration rate. Ethics and dissemination This study has been approved by St Vincent’s Hospital Human Research Ethics Committee (2021/ETH12184). The findings will be presented at national and international scientific meetings and published in peer-reviewed journals. Trial registration number ACTRN12622000978763." @default.
• W4361295066 created "2023-03-31" @default.
• W4361295066 creator A5000616423 @default.
• W4361295066 creator A5001212969 @default.
• W4361295066 creator A5012237355 @default.
• W4361295066 creator A5019085520 @default.
• W4361295066 creator A5030081847 @default.
• W4361295066 creator A5052061327 @default.
• W4361295066 creator A5072611611 @default.
• W4361295066 creator A5078884757 @default.
• W4361295066 creator A5086510117 @default.
• W4361295066 creator A5091151702 @default.
• W4361295066 date "2023-03-01" @default.
• W4361295066 modified "2023-10-07" @default.
• W4361295066 title "Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial" @default.
• W4361295066 cites W1917835527 @default.
• W4361295066 cites W1996143753 @default.
• W4361295066 cites W2090386787 @default.
• W4361295066 cites W2093274439 @default.
• W4361295066 cites W2146264128 @default.
• W4361295066 cites W2600815497 @default.
• W4361295066 cites W2607071925 @default.
• W4361295066 cites W2611078024 @default.
• W4361295066 cites W2798360545 @default.
• W4361295066 cites W2905936571 @default.
• W4361295066 cites W2921909972 @default.
• W4361295066 cites W2940695156 @default.
• W4361295066 cites W2974260792 @default.
• W4361295066 cites W3015096016 @default.
• W4361295066 cites W3036747024 @default.
• W4361295066 cites W3081830235 @default.
• W4361295066 cites W3098234982 @default.
• W4361295066 cites W3102766101 @default.
• W4361295066 cites W3192234234 @default.
• W4361295066 cites W3193297191 @default.
• W4361295066 cites W4200378511 @default.
• W4361295066 cites W4291788046 @default.
• W4361295066 doi "https://doi.org/10.1136/bmjopen-2022-069641" @default.
• W4361295066 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36990488" @default.
• W4361295066 hasPublicationYear "2023" @default.
• W4361295066 type Work @default.
• W4361295066 citedByCount "0" @default.
• W4361295066 crossrefType "journal-article" @default.
• W4361295066 hasAuthorship W4361295066A5000616423 @default.
• W4361295066 hasAuthorship W4361295066A5001212969 @default.
• W4361295066 hasAuthorship W4361295066A5012237355 @default.
• W4361295066 hasAuthorship W4361295066A5019085520 @default.
• W4361295066 hasAuthorship W4361295066A5030081847 @default.
• W4361295066 hasAuthorship W4361295066A5052061327 @default.
• W4361295066 hasAuthorship W4361295066A5072611611 @default.
• W4361295066 hasAuthorship W4361295066A5078884757 @default.
• W4361295066 hasAuthorship W4361295066A5086510117 @default.
• W4361295066 hasAuthorship W4361295066A5091151702 @default.
• W4361295066 hasBestOaLocation W43612950661 @default.
• W4361295066 hasConcept C126322002 @default.
• W4361295066 hasConcept C134018914 @default.
• W4361295066 hasConcept C142724271 @default.
• W4361295066 hasConcept C168563851 @default.
• W4361295066 hasConcept C204787440 @default.
• W4361295066 hasConcept C27081682 @default.
• W4361295066 hasConcept C2775887513 @default.
• W4361295066 hasConcept C2777180221 @default.
• W4361295066 hasConcept C2778198053 @default.
• W4361295066 hasConcept C2778653478 @default.
• W4361295066 hasConcept C2911091166 @default.
• W4361295066 hasConcept C555293320 @default.
• W4361295066 hasConcept C71924100 @default.
• W4361295066 hasConcept C78085059 @default.
• W4361295066 hasConceptScore W4361295066C126322002 @default.
• W4361295066 hasConceptScore W4361295066C134018914 @default.
• W4361295066 hasConceptScore W4361295066C142724271 @default.
• W4361295066 hasConceptScore W4361295066C168563851 @default.
• W4361295066 hasConceptScore W4361295066C204787440 @default.
• W4361295066 hasConceptScore W4361295066C27081682 @default.
• W4361295066 hasConceptScore W4361295066C2775887513 @default.
• W4361295066 hasConceptScore W4361295066C2777180221 @default.
• W4361295066 hasConceptScore W4361295066C2778198053 @default.
• W4361295066 hasConceptScore W4361295066C2778653478 @default.
• W4361295066 hasConceptScore W4361295066C2911091166 @default.
• W4361295066 hasConceptScore W4361295066C555293320 @default.
• W4361295066 hasConceptScore W4361295066C71924100 @default.
• W4361295066 hasConceptScore W4361295066C78085059 @default.
• W4361295066 hasFunder F4320320442 @default.
• W4361295066 hasFunder F4320320475 @default.
• W4361295066 hasIssue "3" @default.
• W4361295066 hasLocation W43612950661 @default.
• W4361295066 hasLocation W43612950662 @default.
• W4361295066 hasLocation W43612950663 @default.
• W4361295066 hasOpenAccess W4361295066 @default.
• W4361295066 hasPrimaryLocation W43612950661 @default.
• W4361295066 hasRelatedWork W1523196181 @default.
• W4361295066 hasRelatedWork W2620245977 @default.
• W4361295066 hasRelatedWork W3093992036 @default.
• W4361295066 hasRelatedWork W3111618423 @default.
• W4361295066 hasRelatedWork W3214641872 @default.
• W4361295066 hasRelatedWork W4200586754 @default.
• W4361295066 hasRelatedWork W4283804282 @default.
• W4361295066 hasRelatedWork W4285499019 @default.

• next